Avadel Pharmaceuticals Crecimiento futuro
Future controles de criterios 6/6
Se prevé un crecimiento anual de los beneficios y los ingresos de Avadel Pharmaceuticals de 62.2% y 30.7% por año respectivamente. Se prevé que el BPA crezca en un 62.8% al año. Se espera que la rentabilidad financiera sea de 144.6% en 3 años.
Información clave
62.2%
Tasa de crecimiento de los beneficios
63.0%
Tasa de crecimiento del BPA
Crecimiento de los beneficios de Pharmaceuticals | 23.7% |
Tasa de crecimiento de los ingresos | 30.7% |
Rentabilidad financiera futura | 144.6% |
Cobertura de analistas | Good |
Última actualización | 28 Aug 2024 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Avadel Pharmaceuticals: The Oxybate War With Jazz Waxes On
Sep 03Avadel Pharmaceuticals: Inflection Point Ahead
Jun 16Avadel Pharmaceuticals: A Deep Dive Into Lumryz's Once-Nightly Revolution
Apr 02Avadel Pharmaceuticals: Robust Launch Of Lumryz And Eased Litigation Overhang
Mar 05Avadel Pharmaceuticals: Strong Launch Of Lumryz With A Legal Risk Backdrop
Jan 28Is Avadel Pharmaceuticals (NASDAQ:AVDL) Weighed On By Its Debt Load?
Jan 16Avadel May Continue To Outperform With Positive Launch Momentum
Jan 11Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt Sensibly?
Sep 22Are Investors Undervaluing Avadel Pharmaceuticals plc (NASDAQ:AVDL) By 49%?
Aug 01Is There An Opportunity With Avadel Pharmaceuticals plc's (NASDAQ:AVDL) 45% Undervaluation?
May 03Avadel Pharmaceuticals filed for 500M mixed shelf offering
Aug 31Avadel Pharmaceuticals Q2 2022 Earnings Preview
Aug 08Avadel Pharmaceuticals (NASDAQ:AVDL) Is Carrying A Fair Bit Of Debt
Jul 07Avadel rises 18% as it expects tentative approval for sleep disorder drug; expects final approval by June 2023
Jun 29Avadel: Further Delay, But Some Light At The End Of The Tunnel
Jun 16Avadel Pharmaceuticals Plc: Initiating Buy, Bye Bye To Sleepiness
Mar 21Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?
Mar 15Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?
Nov 19Avadel Pharmaceuticals: I Am Holding
Nov 01Avadel Pharmaceuticals, The Jazz-Killer
Aug 05Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt In A Risky Way?
Jul 23Avadel presents new clinical data from Phase 3 REST-ON trial of FT218 in narcolepsy
Jun 09Avadel Pharmaceuticals EPS beats by $0.09
May 10Need To Know: The Consensus Just Cut Its Avadel Pharmaceuticals plc (NASDAQ:AVDL) Estimates For 2021
Mar 11Is Avadel Pharmaceuticals plc (NASDAQ:AVDL) Popular Amongst Institutions?
Feb 05Avadel Pharmaceuticals' (NASDAQ:AVDL) Stock Price Has Reduced 35% In The Past Three Years
Jan 10Previsiones de crecimiento de beneficios e ingresos
Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
---|---|---|---|---|---|
12/31/2026 | 401 | 142 | N/A | 150 | 7 |
12/31/2025 | 301 | 57 | N/A | 56 | 9 |
12/31/2024 | 174 | -48 | N/A | -29 | 9 |
6/30/2024 | 95 | -106 | -114 | -114 | N/A |
3/31/2024 | 55 | -157 | -128 | -128 | N/A |
12/31/2023 | 28 | -160 | -129 | -129 | N/A |
9/30/2023 | 9 | -159 | -116 | -116 | N/A |
6/30/2023 | 1 | -143 | -85 | -84 | N/A |
3/31/2023 | N/A | -142 | -67 | -66 | N/A |
12/31/2022 | N/A | -137 | -71 | -70 | N/A |
9/30/2022 | N/A | -132 | -78 | -77 | N/A |
6/30/2022 | N/A | -134 | -92 | -92 | N/A |
3/31/2022 | N/A | -90 | -88 | -88 | N/A |
12/31/2021 | N/A | -77 | -77 | -77 | N/A |
9/30/2021 | N/A | -66 | -74 | -74 | N/A |
6/30/2021 | N/A | -56 | -63 | -63 | N/A |
3/31/2021 | 10 | -6 | -61 | -61 | N/A |
12/31/2020 | 22 | 7 | -49 | -49 | N/A |
9/30/2020 | 33 | 16 | -38 | -38 | N/A |
6/30/2020 | 48 | 18 | -35 | -35 | N/A |
3/31/2020 | 55 | -21 | -29 | -29 | N/A |
12/31/2019 | 59 | -33 | -38 | -38 | N/A |
9/30/2019 | 69 | -94 | -55 | -55 | N/A |
6/30/2019 | 75 | -101 | -68 | -67 | N/A |
3/31/2019 | 86 | -96 | -106 | -86 | N/A |
12/31/2018 | 103 | -95 | -103 | -83 | N/A |
9/30/2018 | 117 | -40 | -93 | -72 | N/A |
6/30/2018 | 137 | -2 | -128 | -55 | N/A |
3/31/2018 | 154 | 30 | N/A | -27 | N/A |
12/31/2017 | 173 | 68 | N/A | 17 | N/A |
9/30/2017 | 182 | 81 | N/A | 38 | N/A |
6/30/2017 | 174 | 40 | N/A | 37 | N/A |
3/31/2017 | 167 | -9 | N/A | 24 | N/A |
12/31/2016 | 150 | -41 | N/A | 19 | N/A |
9/30/2016 | 152 | 28 | N/A | 38 | N/A |
6/30/2016 | 167 | 19 | N/A | 61 | N/A |
3/31/2016 | 177 | 23 | N/A | 79 | N/A |
12/31/2015 | 173 | 42 | N/A | 84 | N/A |
9/30/2015 | 127 | -64 | N/A | 52 | N/A |
6/30/2015 | 87 | -46 | N/A | 36 | N/A |
3/31/2015 | 43 | -49 | N/A | 17 | N/A |
12/31/2014 | 15 | -89 | N/A | -11 | N/A |
9/30/2014 | 4 | -56 | N/A | -11 | N/A |
6/30/2014 | 2 | -52 | N/A | -15 | N/A |
3/31/2014 | 4 | -65 | N/A | -15 | N/A |
12/31/2013 | 4 | -47 | N/A | -21 | N/A |
9/30/2013 | 24 | -39 | N/A | -20 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Se prevé que AVDL sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2.4%).
Beneficios vs. Mercado: Se prevé que AVDL sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.
Beneficios de alto crecimiento: Se espera que AVDL sea rentable en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos (30.7% al año) de AVDL crezcan más rápidamente que los del mercado US (8.8% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos (30.7% al año) de AVDL crezcan más rápidamente que un 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Se prevé que la rentabilidad financiera de AVDL sea muy elevada dentro de 3 años (155.3%).